Mineralocorticoid Receptor Antagonist
Screening for albuminuria may identify candidates for finerenone
BOSTON — Finerenone reduces CV and renal events in patients with type 2 diabetes and chronic kidney disease, and albuminuria is a good screening tool to identify candidates, according to a speaker.
‘Huge flurry of activity’ occurring in treatments for resistant hypertension
LOUISVILLE, Ky. — Various potential treatments for patients with resistant hypertension should come on the market within the next few years, a speaker said during the American Society for Preventive Cardiology Congress on CVD Prevention.
Nonsteroidal MRAs ‘save lives’ in diabetes with cardiorenal disease
PHILADELPHIA — For adults with type 2 diabetes and chronic kidney disease, a novel nonsteroidal mineralocorticoid receptor antagonist can play a key role in reducing risk for serious cardiorenal outcomes, according to a speaker.
VIDEO: Bozkurt highlights main takeaways from new HF management guideline
WASHINGTON — In this Healio video exclusive, the vice chair of a new guideline on the management of HF discusses the biggest takeaways.
Updated guideline redefines HF stages, emphasizes prevention, new treatments
WASHINGTON — A joint guideline from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America redefines HF stages to focus on prevention and recommends HF treatment with SGLT2 inhibitors.
Mineralocorticoid receptor antagonist use does not affect empagliflozin benefit in HFpEF
The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.
In HFrEF, therapy in patients with frailty often not optimized despite high risk
In patients with HF with reduced ejection fraction, those with frailty had elevated risk for poor outcomes but less likelihood of being on optimal guideline-directed medical therapy, according to new data from the GUIDE-IT trial.
Mineralocorticoid receptor antagonists may stave off renal replacement therapy in CKD
In a real-world outpatient population, mineralocorticoid receptor antagonist use in patients with chronic kidney disease was associated with lower rates of renal replacement therapy initiation compared with nonuse, researchers reported.
Top in endocrinology: Aldosterone antagonists, hormone deficiency
Mineralocorticoid receptor antagonists have an important role in diabetic kidney disease and related cardiovascular consequences, according to a speaker at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
Mineralocorticoid receptor antagonist use does not affect empagliflozin HF, renal benefits
The use of mineralocorticoid receptor antagonists did not influence the ability of empagliflozin to reduce adverse HF and renal outcomes, according to data from EMPEROR-Reduced published in the Journal of the American College of Cardiology.